Literature DB >> 14693542

Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum.

Satoshi Sobue1, Kaneo Sekiguchi, Toshitaka Nabeshima.   

Abstract

We have compared the distribution of fluconazole (FLC) with that of itraconazole (ITC) and griseofulvin (GRF) in the abdominal skin tissues after a single oral dose was administered to guinea pigs. The FLC concentrations in the stratum corneum reached a peak at 2 h after administration and were similar to those of ITC and higher than those of GRF in spite of the administration of a lower dose. GRF was eliminated from the stratum corneum faster than FLC and ITC. The FLC concentrations were also remarkably higher than those of ITC and GRF in the epidermis-cutis but lower in the subcutaneous fatty tissue. The distribution characteristics of each drug result from differences in their physicochemical properties. Following the administration of multiple doses, the FLC concentrations in the stratum corneum were highest in the abdominal skin tissues; those at 24 h after each administration increased gradually and were maintained at a level more than 10 times higher than that of the plasma concentrations. The FLC concentrations in the planta pedis stratum corneum and in the nail showed good dose proportionality and obvious accumulation and were 60 and 40 times as high as that in plasma on day 14. The extent of binding of FLC to human corneous keratin in vitro was about 10%, which is lower than those of ITC (94 to 97%) and GRF (36 to 38%). FLC, unlike ITC, therefore, is presumed to exist in the stratum corneum at high concentrations in an active nonbinding form. These excellent intracutaneous pharmacokinetic properties of FLC probably account in large part for the in vivo efficacy of FLC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693542      PMCID: PMC310182          DOI: 10.1128/AAC.48.1.216-223.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparison of the therapeutic efficacy of oral doses of fluconazole and griseofulvin in a guinea pig model of dermatophytosis.

Authors:  K Nagino; H Shimohira; M Ogawa; K Uchida; H Yamaguchi
Journal:  J Antibiot (Tokyo)       Date:  2000-02       Impact factor: 2.649

2.  Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography.

Authors:  J H Rex; L H Hanson; M A Amantea; D A Stevens; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Comparison of the therapeutic efficacy of oral doses of fluconazole and itraconazole in a guinea pig model of dermatophytosis.

Authors:  K Nagino; H Shimohira; M Ogawa; K Uchida; H Yamaguchi
Journal:  J Infect Chemother       Date:  2000-03       Impact factor: 2.211

4.  In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.

Authors:  Y Tatsumi; M Yokoo; T Arika; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates.

Authors:  C J Jessup; J Warner; N Isham; I Hasan; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat.

Authors:  J Faergemann; H Laufen
Journal:  Clin Exp Dermatol       Date:  1993-03       Impact factor: 3.470

7.  The in vitro activity of fluconazole against fungi involved in dermal infections.

Authors:  A Wildfeuer; H P Seidl
Journal:  Mycoses       Date:  1994 Nov-Dec       Impact factor: 4.377

8.  KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs.

Authors:  Yoshiyuki Tatsum; Mamoru Yokoo; Tadashi Arika; Hideyo Yamaguchi
Journal:  Microbiol Immunol       Date:  2002       Impact factor: 1.955

9.  [In vivo and in vitro antifungal activity of fluconazole].

Authors:  K Kawasaki; Y Matsumura; M Ogawa; A Tsuji; T Matsunaga; S Goto
Journal:  Jpn J Antibiot       Date:  1991-05

10.  Bioavailability of fluconazole in the skin after oral medication.

Authors:  A Wildfeuer; J Faergemann; H Laufen; G Pfaff; T Zimmermann; H P Seidl; P Lach
Journal:  Mycoses       Date:  1994 Mar-Apr       Impact factor: 4.377

View more
  10 in total

1.  The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.

Authors:  Keita Sugiura; Noriaki Sugimoto; Shinya Hosaka; Maria Katafuchi-Nagashima; Yoshio Arakawa; Yoshiyuki Tatsumi; William Jo Siu; Radhakrishnan Pillai
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.

Authors:  E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; L Long; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

Review 3.  A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation.

Authors:  Claudia Suenderhauf; Neil Parrott
Journal:  Pharm Res       Date:  2012-11-21       Impact factor: 4.200

4.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

5.  In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.

Authors:  Kelly de Wit; Caroline Paulussen; An Matheeussen; Koen van Rossem; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

6.  In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.

Authors:  D M Saunte; F Simmel; N Frimodt-Moller; L B Stolle; E L Svejgaard; M Haedersdal; C Kloft; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Trans-ungual delivery of itraconazole hydrochloride by iontophoresis.

Authors:  Avadhesh Kushwaha; Melissa Jacob; H N Shiva Kumar; Shobharani Hiremath; Sacchidanand Aradhya; Michael A Repka; S Narasimha Murthy
Journal:  Drug Dev Ind Pharm       Date:  2014-12-08       Impact factor: 3.225

8.  The role of corneocytes in skin transport revised--a combined computational and experimental approach.

Authors:  Steffi Hansen; Arne Naegel; Michael Heisig; Gabriel Wittum; Dirk Neumann; Karl-Heinz Kostka; Peter Meiers; Claus-Michael Lehr; Ulrich F Schaefer
Journal:  Pharm Res       Date:  2009-02-25       Impact factor: 4.200

Review 9.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

10.  New, Biocompatible, Chitosan-Gelled Microemulsions Based on Essential Oils and Sucrose Esters as Nanocarriers for Topical Delivery of Fluconazole.

Authors:  Lavinia Vlaia; Ioana Olariu; Ana Maria Muţ; Georgeta Coneac; Vicenţiu Vlaia; Dan Florin Anghel; Monica Elisabeta Maxim; Gabriela Stângă; Amadeus Dobrescu; Maria Suciu; Zoltan Szabadai; Dumitru Lupuleasa
Journal:  Pharmaceutics       Date:  2021-12-29       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.